SUNNYVALE, Calif.--(BUSINESS WIRE)--Pharmacyclics, Inc. (NASDAQ:PCYC) today announced an update to its clinical programs targeting histone deacetylase (HDAC) with its drug candidate PCI-24781 that is currently in multiple clinical trials for treating various solid and hematologic tumors. In addition, the Company announced multiple presentations regarding its orally available HDAC inhibitor compound at the annual AACR meeting in Denver, Colorado.
